Projects per year
Fingerprint
Dive into the research topics where Karel Fostier is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Finished
Research output
-
The road to personalized myeloma medicine: Patient-specific single-domain antibodies for anti-idiotypic radionuclide therapy
Puttemans, J., Stijlemans, B., Keyaerts, M., Vander Meeren, S., Renmans, W., Fostier, K., Debie, P., Hanssens, H., Rodak, M., Pruszynski, M., De Veirman, K., Vanderkerken, K., Lahoutte, T., Morgenstern, A., Bruchertseifer, F., Devoogdt, N. & D'Huyvetter, M., Jan 2022, In: Molecular Cancer Therapeutics. 21, 1, p. 159-169 11 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile14 Citations (Scopus)206 Downloads (Pure) -
Compass: a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients
Delforge, M., Raddoux, J., Kenis, C., Vanhellemont, A., Mineur, P., Hoornaert, E., Wu, K. L., Caers, J., Van Eygen, K., Kentos, A., Depaus, J., Put, N., Van De Velde, A., Claes, G., Vlummens, P., Maertens, V., Meuleman, N., Broek, I. V., Vaes, M., Fostier, K. & 2 others, , Oct 2021, In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 21, p. S124-S124Research output: Contribution to journal › Meeting abstract (Journal)
-
Validation of a PCR-based next-generation sequencing approach for the detection and quantification of minimal residual disease in acute lymphoblastic leukemia and multiple myeloma using gBlocks as calibrators
Van der Straeten, J., De Brouwer, W., Kanjinga, E. K., Dresse, M-F., Fostier, K., Schots, R., Van Riet, I. & Bakkus, M., May 2021, In: The Journal of Molecular Diagnostics. 23, 5, p. 599-611 13 p.Research output: Contribution to journal › Article › peer-review
Open Access5 Citations (Scopus) -
COVID-19, impact on myeloma patients
Dufour, I., Raedemaeker, J., Andreozzi, F., Verstraete, G., Bailly, S., Delforge, M., Storms, P., Jacquy, C., Van de Velde, A., Mineur, P., Lejeune, M., Bauwens, D., Van Obbergh, F., Kentos, A., Nguyen, J., Fostier, K., De Weweire, A., Meuleman, N. & Vekemans, M-C., Aug 2020, In: Annals of Hematology. 99, 8, p. 1947-1949 3 p.Research output: Contribution to journal › Article › peer-review
Open Access9 Citations (Scopus)1 Downloads (Pure) -
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial
IFM2014-04 investigators, Nov 2019, In: British Journal of Haematology. 187, 3, p. 319-327 9 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile23 Citations (Scopus)28 Downloads (Pure)